Ivaltinostat
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects[1][2][3][4].
Product Specifications
CAS Number
936221-33-9
Product Name Alternative
CG-200745
UNSPSC
12352005
Target
Apoptosis; HDAC; MDM-2/p53
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cg-200745.html
Solubility
10 mM in DMSO
Smiles
O=C(NCCCN(C)C)/C(COC1=C2C=CC=CC2=CC=C1)=C/CCCCC(NO)=O
Molecular Formula
C24H33N3O4
Molecular Weight
427.54
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HDAC
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MAD2L1 binding protein (MAD2L1BP) (NM_014628) Human Over-expression Lysate
Serum Amyloid P / APCS (APCS/3240), CF740 conjugate, 0.1mg/mL
